Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Standigm uses Synthia Retrosynthesis Software from Merck KGaA, Darmstadt, Germany, to accelerate its drug design and synthesis processes driving advancements in pharmaceutical development. Standigm ...

We recently compiled a list of the 8 Best US Stocks For Foreign Investors Right Now. In this article, we are going to take a ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

On October 8, 2024, PhRMA held a media briefing to address growing concerns over the Inflation Reduction Act (IRA) and its effects on the biopharmaceutical industry, Medicare Part D beneficiaries, and ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

While you may think of healthcare as only covering human health, animal and pet health is also a growing sector. Click to ...